CD62L is not a reliable biomarker for predicting PML risk in natalizumab-treated R-MS patients (Q36645170)
Jump to navigation
Jump to search
scientific article published on 30 December 2015
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | CD62L is not a reliable biomarker for predicting PML risk in natalizumab-treated R-MS patients |
scientific article published on 30 December 2015 |
Statements
1 reference
CD62L is not a reliable biomarker for predicting PML risk in natalizumab-treated R-MS patients (English)
1 reference
Richard M Ransohoff
1 reference
Linda A Lieberman
1 reference
Wanyong Zeng
1 reference
Carol Singh
1 reference
Wenting Wang
1 reference
Kevin L Otipoby
1 reference
Christine Loh
1 reference
Tatiana Plavina
1 reference
Leonid Gorelik
1 reference
Ellen Cahir-McFarland
1 reference
1 reference
Identifiers
1 reference